A recent study suggests that patients who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional lifestyle programs.
Research printed in a major medical journal points out that while obese individuals frequently drop a large proportion of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users using such treatments need to be informed of the risk of quick rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to starting mass in about one and a half years.
Comparing Approaches
The analysis, which examined dozens of trials involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.
Researchers point out that people who lose weight through dieting typically experience a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Fast Regain
Doctors believe the way of the drugs explains the heightened rebound.
The injections mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to produce less of its endogenous GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Health authorities advise the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, due to the high risk of relapse, the treatment might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who state that the results "highlight the chronic nature of excess weight," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs explain a intense return of appetite.
"It was like a switch flipping and I was suddenly starving," said an individual.
This difficulty is compounded if users have not developed permanent dietary or behavioural modifications during therapy.
Significant Use
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is greater among females compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on integrated lifestyle support.
